Dataset from A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension

The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.

本研究旨在评估每日一次（QD）给药的阿齐沙坦酯（azilsartan medoxomil）对比安慰剂与奥美沙坦（olmesartan），用于原发性高血压（essential hypertension）受试者的安全性与有效性。